Nutriband rises as Noble Capital starts coverage with 'outperform'

Nutriband

22/01/2025 15:55

** Shares of transdermal pharma products maker Nutriband
 NTRB.O  rise ~28% to $6.67
    ** Brokerage Noble Capital starts coverage on NTRB with
"outperform" rating and sets PT at $13
    ** PT represents a 148% upside to the stock's last
    ** NTRB is developing Aversa, a proprietary technology that
makes transdermal patches safer by preventing abuse and misuse
of potent opioids like fentanyl
    ** Brokerage says NTRB's tech has "abuse-deterrent" features
that differentiate it from other transdermal patches on the
market
    ** Also notes NTRB's partnership to add the Aversa
technology to Kindeva's transdermal fentanyl patch could be a
highly effective means to stop misuse
    ** NTRB shares doubled in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))